{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:54:46Z","timestamp":1792364086039,"version":"4.4.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.autrev.2023.103375","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T03:06:32Z","timestamp":1686625592000},"page":"103375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature"],"prefix":"10.1016","volume":"22","author":[{"given":"N\u00e9stor L\u00f3pez","family":"Guerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Matas-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Serra-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morgado-Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Padrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iban","family":"Aldecoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Duque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Casal-Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mu\u00f1oz-Braceras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Aranega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moreno-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Cant\u00f3-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gl\u00f2ria","family":"Garrabou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbaliz","family":"Ruiz-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Trallero-Araguas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Selva-O'Callaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Grau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiram","family":"Torres-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iago Pinal","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 C.","family":"Milisenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103375_bb0005","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41598-020-58674-4","article-title":"Clinical efficacy and safety of anti-PD-1\/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis","volume":"10","author":"Sun","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2023.103375_bb0010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2051-1426-1-12","article-title":"Primer on tumor immunology and cancer immunotherapy","volume":"1","author":"Harris","year":"2013","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2023.103375_bb0015","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.autrev.2023.103375_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2023.103375_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2023.103375_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160221","article-title":"Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports","volume":"11","author":"Abdel-Wahab","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2023.103375_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2023.103375_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.autrev.2023.103375_bb0045","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European league against rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103375_bb0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.25259\/IJDVL_1306_20","article-title":"Immunotherapy-intensified paraneoplastic dermatomyositis","volume":"88","author":"Estenaga","year":"2021","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.autrev.2023.103375_bb0055","first-page":"120","article-title":"Dermatomyositis, pembrolizumab, and squamous cell carcinoma of the lung","volume":"34","author":"Wiggins","year":"2020","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"6","key":"10.1016\/j.autrev.2023.103375_bb0060","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1093\/rheumatology\/keaa832","article-title":"Anti-TIF1\u03b3 antibody-positive dermatomyositis in a 15-year-old boy with Epstein-Barr virus-related nasopharyngeal cancer receiving nivolumab","volume":"60","author":"Asano","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103375_bb0065","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s12094-019-02214-8","article-title":"Safety and efficacy of PD-1\/PD-L1 blockade in patients with preexisting antinuclear antibodies","volume":"22","author":"Sakakida","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"10.1016\/j.autrev.2023.103375_bb0070","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13555-020-00396-6","article-title":"Toripalimab-induced dermatomyositis in a patient with metastatic melanoma","volume":"10","author":"Lin","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"10.1016\/j.autrev.2023.103375_bb0075","doi-asserted-by":"crossref","DOI":"10.5070\/D3268049887","article-title":"Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature","volume":"26","author":"Messer","year":"2020","journal-title":"Dermatol Online J"},{"issue":"1","key":"10.1016\/j.autrev.2023.103375_bb0080","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10637-020-00974-7","article-title":"Anti-transcriptional intermediary factor 1-\u03b3 antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: a case report","volume":"39","author":"Osaki","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.autrev.2023.103375_bb0085","doi-asserted-by":"crossref","first-page":"e430","DOI":"10.1111\/1346-8138.14993","article-title":"Case of dermatomyositis during treatment with pembrolizumab for lung cancer","volume":"46","author":"Hinogami","year":"2019","journal-title":"J Dermatol"},{"key":"10.1016\/j.autrev.2023.103375_bb0090","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/bjd.17245","article-title":"Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy","volume":"181","author":"Marano","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2023.103375_bb0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CMR.0000000000000642","article-title":"Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature","volume":"30","author":"Kosche","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.autrev.2023.103375_bb0100","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13256-019-2105-9","article-title":"Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report","volume":"13","author":"Shibata","year":"2019","journal-title":"J Med Case Reports"},{"key":"10.1016\/j.autrev.2023.103375_bb0105","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jdcr.2018.08.006","article-title":"Wong-type dermatomyositis during anti-PD-1 therapy","volume":"4","author":"Yu","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.autrev.2023.103375_bb0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejca.2018.08.021","article-title":"Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma","volume":"104","author":"Berger","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2023.103375_bb0115","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2169\/internalmedicine.9381-17","article-title":"Advanced lung adenocarcinoma with nivolumab-associated dermatomyositis","volume":"57","author":"Kudo","year":"2018","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2023.103375_bb0120","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 inhibitor-associated myopathies: emerging immune-mediated myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2023.103375_bb0125","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1684\/ejd.2016.2770","article-title":"A case of drug-associated dermatomyositis following ipilimumab therapy","volume":"26","author":"Yamaguchi","year":"2016","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.autrev.2023.103375_bb0130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamadermatol.2014.2233","article-title":"Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade","volume":"151","author":"Sheik Ali","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2023.103375_bb0135","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103375_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garcia","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103375_bb0145","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.autrev.2023.103375_bb0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/2326-6066.CIR-13-0146","article-title":"Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis","volume":"2","author":"Min","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.autrev.2023.103375_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/CJI.0000000000000172","article-title":"Inflammatory myopathy and axonal neuropathy in a patient with melanoma following Pembrolizumab treatment","volume":"40","author":"Diamantopoulos","year":"2017","journal-title":"J Immunother"},{"key":"10.1016\/j.autrev.2023.103375_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102455","article-title":"Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern","volume":"19","author":"Matas-Garcia","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103375_bb0165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semarthrit.2014.04.004","article-title":"Dermatomyositis presenting with severe subcutaneous edema: five additional cases and review of the literature","volume":"44","author":"Milisenda","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103375_bb0170","article-title":"Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis","volume":"9","author":"Lu","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.autrev.2023.103375_bb0175","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/rheumatology\/kex413","article-title":"Tumour TIF1 mutations and loss of heterozygosity related to cancer-associated myositis","volume":"57","author":"Pinal-Fernandez","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103375_bb0180","doi-asserted-by":"crossref","first-page":"5863","DOI":"10.1093\/rheumatology\/keab260","article-title":"TRIM33 gene somatic mutations identified by next generation sequencing in neoplasms of patients with anti-TIF1gamma positive cancer-associated dermatomyositis","volume":"60","author":"Cordel","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2023.103375_bb0185","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/js.2017-00432","article-title":"Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab: a prospective study","volume":"2","author":"Kobayashi","year":"2018","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.autrev.2023.103375_bb0190","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.autrev.2023.103375_bb0195","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2023.103375_bb0200","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722300109X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722300109X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:29:52Z","timestamp":1761600592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722300109X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S156899722300109X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103375","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103375"}}